Lipigon Pharmaceuticals AB (publ) (LPGO.ST)
SEK 0.17
(-4.69%)
SEK 0.17
(-4.69%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | -5.11 Million SEK | -3536.34% |
| 2022 | 366 Thousand SEK | 100.92% |
| 2021 | -39.94 Million SEK | -418.95% |
| 2020 | -7.69 Million SEK | -110.1% |
| 2019 | -3.66 Million SEK | -122233.33% |
| 2018 | 3000.00 SEK | 100.13% |
| 2017 | -2.27 Million SEK | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | -325 Thousand SEK | 23300.0% |
| 2024 Q1 | -6000.00 SEK | 0.0% |
| 2023 FY | -12.57 Million SEK | -3536.34% |
| 2023 Q2 | 7.08 Million SEK | 118200.0% |
| 2023 Q1 | -6000.00 SEK | -101.56% |
| 2023 Q4 | -6000.00 SEK | 99.89% |
| 2023 Q3 | -5.4 Million SEK | -176.25% |
| 2022 Q3 | -6000.00 SEK | 50.0% |
| 2022 Q4 | 384 Thousand SEK | 6500.0% |
| 2022 Q2 | -12 Thousand SEK | 99.84% |
| 2022 Q1 | -7.37 Million SEK | 48.69% |
| 2022 FY | 366 Thousand SEK | 100.92% |
| 2021 FY | -39.94 Million SEK | -418.95% |
| 2021 Q2 | -10.03 Million SEK | -175.03% |
| 2021 Q4 | -14.36 Million SEK | -28.04% |
| 2021 Q1 | -3.64 Million SEK | 21.12% |
| 2021 Q3 | -11.21 Million SEK | -11.78% |
| 2020 Q1 | -278 Thousand SEK | 0.0% |
| 2020 FY | -7.69 Million SEK | -110.1% |
| 2020 Q4 | -4.62 Million SEK | -2085.41% |
| 2020 Q3 | 233 Thousand SEK | 125.8% |
| 2020 Q2 | -903 Thousand SEK | -224.82% |
| 2019 FY | -3.66 Million SEK | -122233.33% |
| 2018 FY | 3000.00 SEK | 100.13% |
| 2017 FY | -2.27 Million SEK | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | -160.68 Million SEK | 96.816% |
| Ziccum AB (publ) | -23.28 Million SEK | 78.025% |
| Modus Therapeutics Holding AB (publ) | - SEK | Infinity% |
| BioArctic AB (publ) | 346.31 Million SEK | 101.478% |
| Sprint Bioscience AB (publ) | 41.78 Million SEK | 112.245% |
| Mendus AB (publ) | 28.48 Million SEK | 117.963% |
| Genovis AB (publ.) | 54 Million SEK | 109.476% |
| Intervacc AB (publ) | -13.79 Million SEK | 62.904% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 2.17 Million SEK | 335.698% |
| Active Biotech AB (publ) | -1.67 Million SEK | -205.493% |
| Magle Chemoswed Holding AB (publ) | 9.96 Million SEK | 151.36% |
| Bio-Works Technologies AB (publ) | 26.82 Million SEK | 119.078% |
| Aptahem AB (publ) | 2.63 Million SEK | 294.515% |
| Vicore Pharma Holding AB (publ) | -3.42 Million SEK | -49.576% |
| Kancera AB (publ) | -1.96 Million SEK | -160.407% |
| Infant Bacterial Therapeutics AB (publ) | 77 Thousand SEK | 6745.455% |
| Fluicell AB (publ) | 1.73 Million SEK | 394.419% |
| Saniona AB (publ) | 11.78 Million SEK | 143.434% |
| Biovica International AB (publ) | 6.87 Million SEK | 174.407% |
| Spago Nanomedical AB (publ) | -23.28 Million SEK | 78.023% |
| AcouSort AB (publ) | 8.38 Million SEK | 160.997% |
| Xintela AB (publ) | 78 Thousand SEK | 6660.256% |
| Abliva AB (publ) | -35.66 Million SEK | 85.652% |
| Egetis Therapeutics AB (publ) | -146.9 Million SEK | 96.517% |
| Karolinska Development AB (publ) | 2.8 Million SEK | 282.294% |
| OncoZenge AB (publ) | 3000.00 SEK | 170666.667% |
| Amniotics AB (publ) | -1.93 Million SEK | -165.13% |
| 2cureX AB (publ) | -37.48 Million SEK | 86.35% |
| CombiGene AB (publ) | -21.29 Million SEK | 75.966% |
| Asarina Pharma AB (publ) | -423 Thousand SEK | -1109.693% |
| Calliditas Therapeutics AB (publ) | 1.12 Billion SEK | 100.453% |
| Camurus AB (publ) | 1.58 Billion SEK | 100.324% |
| Corline Biomedical AB | 28.38 Million SEK | 118.03% |
| IRLAB Therapeutics AB (publ) | -122.73 Million SEK | 95.831% |
| Isofol Medical AB (publ) | -34.41 Million SEK | 85.131% |
| I-Tech AB | 27.56 Million SEK | 118.563% |
| Hansa Biopharma AB (publ) | 70.95 Million SEK | 107.212% |
| Cyxone AB (publ) | 2.61 Million SEK | 295.979% |
| ExpreS2ion Biotech Holding AB (publ) | 3.4 Million SEK | 250.367% |
| Biosergen AB | -456 Thousand SEK | -1022.149% |
| Cantargia AB (publ) | -3.45 Million SEK | -48.276% |
| NextCell Pharma AB | -43.74 Million SEK | 88.304% |
| Xspray Pharma AB (publ) | -9.19 Million SEK | 44.344% |
| Elicera Therapeutics AB (publ) | 11.21 Million SEK | 145.613% |
| Nanologica AB (publ) | -76 Thousand SEK | -6632.895% |
| SynAct Pharma AB | -778 Thousand SEK | -557.712% |
| Annexin Pharmaceuticals AB (publ) | -193 Thousand SEK | -2551.295% |
| Stayble Therapeutics AB (publ) | - SEK | Infinity% |
| LIDDS AB (publ) | -12.92 Million SEK | 60.401% |
| Lipum AB (publ) | 53 Thousand SEK | 9754.717% |
| BioInvent International AB (publ) | 71.46 Million SEK | 107.161% |
| Alzinova AB (publ) | 19.87 Million SEK | 125.747% |
| Oncopeptides AB (publ) | 36.29 Million SEK | 114.097% |
| Pila Pharma AB (publ) | 1.46 Million SEK | 449.756% |
| Guard Therapeutics International AB (publ) | -15 Thousand SEK | -34013.333% |
| Scandinavian ChemoTech AB (publ) | 1.65 Million SEK | 408.625% |
| Simris Alg AB (publ) | 2 Million SEK | 354.958% |
| Diamyd Medical AB (publ) | -3.58 Million SEK | -42.933% |
| Xbrane Biopharma AB (publ) | 35.38 Million SEK | 114.46% |
| Ascelia Pharma AB (publ) | -1.04 Million SEK | -387.798% |
| Diagonal Bio AB (publ) | 3.13 Million SEK | 263.326% |